OncoSec Medical to Host Corporate Update Conference Call on December 9, 2014
SAN DIEGO-- OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will host a corporate update conference call on Tuesday, December 9, 2014 at 10 AM ET. The call will cover recent milestone achievements and corporate and clinical development strategies, but will not address the company’s results of operations or financial condition for a completed quarterly or annual fiscal period. To participate in the call, dial toll-free (855) 801-3670 in the U.S. and Canada or (804) 681-3878 outside the U.S. and Canada and enter conference ID #48289768.
A replay of the conference call will be available 2 hours after the call’s completion through January 23, 2015. To access this recording, dial (855) 859-2056 in the U.S. and Canada or (404) 537-3406 outside the U.S. and Canada and enter conference ID #48289768.
To listen to the conference call, dial in approximately ten minutes before the scheduled call. An archived replay of the call will also be available through the investors page at www.oncosec.com. Invited participants may ask questions during the conference call. Others may submit questions before the call by e-mail addressed to email@example.com. Submitted questions will be screened for appropriateness and general interest. Selected questions received with sufficient notice before the call will be answered as time permits at the end of the call. For further information, contact OncoSec's Investor Relations department by phone at (855) 662-6732 or by email at firstname.lastname@example.org
About OncoSec Medical
OncoSec Medical Inc. is a biopharmaceutical company developing its investigational ImmunoPulse intratumoral cancer immunotherapy. OncoSec Medical's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec's lead program evaluating ImmunoPulse for the treatment of metastatic melanoma is currently in Phase 2 development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches. For more information, please visit www.oncosec.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
Source: OncoSec Medical Inc.